Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02588339 · ClinicalTrials.gov registry record · Phase 2
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02588339 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 42 participants.
The verdict
NCT02588339, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in combination with sirolimus and tacrolimus will help reduce the incidence of Graft-vs-host disease (GVHD).
Interventions
- DRUG Sirolimus
- DRUG Tacrolimus
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-03-04 |
| Est. Completion | 2021-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02588339
The ClinicalTrials.gov registry entry for NCT02588339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sirolimus is the first listed.
NCT02588339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02588339 about?
NCT02588339 is a clinical study titled "Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention". This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in combination with sirolimus and tacrolimus will help reduce the incidence of Graft-vs-host disease (GVHD).
What is the current status of trial NCT02588339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-03-04. Estimated completion is 2021-07-13.
What interventions are being tested in trial NCT02588339?
The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT02588339?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.